Newsroom – Page 2

Home
-
Newsroom

~~Latest news~~

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

[Newsletter] XENONEWS

June 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

[ Press Information ] APPOINTMENTS

April 2022. # Download our press information (english version) # Télécharger notre...

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

January 2022. # Download our press information (english version) # Télécharger notre...

[Newsletter] XENONEWS

February 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

[Newsletter] XENONEWS

December 2021. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.

# Download our press information (english version) # Télécharger notre information presse...

[Newsletter] XENONEWS

October 2021 >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Release] XENOTHERA signs a memorandum of understanding with the Vietnamese conglomerate Vingroup

September 9,2021. # Download our press release (english version) # Télécharger notre...

[Press Release] Accelarated Scientific Advise from European Medicines Adgency EMA for XAV19 Market Authorisation

July 8, 2021. # Download our press release (english version) # Télécharger...

[Newsletter] XENONEWS

Summer 2021. >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Release] 20 M€ raised by XENOTHERA to accelerate its development

June 29, 2021. # Download our press release (english version) # Télécharger...

[Press Alert] XENOTHERA signs a pre-order contract of its anti-covid treatment with the French government

May 11, 2021. # Download our press information (english version) # Télécharger...

[Newsletter] XENONEWS

May 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Alert] XENOTHERA And Its Partner Excelya Announce the Recruitment of the First Patient in The EUROXAV Clinical Trial of its COVID Treatment XAV19

May 3, 2021. # Download our press information (english version) # Télécharger...

[Newsletter] XENONEWS

April 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Release] Completion of patients’ enrolment in the POLYCOR clinical trial promoted by the Nantes University Hospital

April 21, 2021. # Download our press release (english version) # Télécharger...

[Press Release] Effectiveness of XAV19 against SARS-CoV-2 variants

February 1, 2021. # Download our press release (english version) # Télécharger...

[Newsletter] XENONEWS

March 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Newsletter] XENONEWS

February 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Newsletter] XENONEWS

January 2021 >> Official XENOTHERA newsletter /Lettre d’information officielle de XENOTHERA <<...

[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody

December 2021. # Download our press information (english version) # Télécharger notre...